Why Nasdaq-Listed Afya Is Slipping Ahead of Its Next Earnings Report
Wall Street analysts adjust their expectations for Brazilian medical education provider Afya Limited as merger integration questions loom.
US retail investors looking to diversify into international markets often face the hurdle of trading foreign-listed companies through American Depositary Receipts, which can carry extra administrative fees and liquidity constraints. However, a select group of foreign companies bypass this structure entirely by choosing a primary listing directly on US exchanges. One such company, the Brazilian medical education provider Afya Limited, experienced a 3.33% drop on November 5, 2026, closing at $10.15 per share on the Nasdaq.
Based in Belo Horizonte, Brazil, Afya operates a massive network of medical schools and digital health services across the country. The company has grown rapidly by acquiring smaller regional colleges to capture the high-margin demand for medical degrees in Latin America's largest economy. Because Brazil faces a structural deficit of doctors in its interior states, the federal government heavily regulates medical school seats, making existing operating licenses highly valuable and defensive assets.
The recent downward pressure on the stock comes as Wall Street recalibrates its expectations ahead of Afya’s third-quarter 2026 earnings release, scheduled for November 12, 2026. On November 5, 2026, Morgan Stanley upgraded the stock rating on valuation but lowered its outlook on the stock's future performance, as reported by Investing.com. This followed a move by JPMorgan on November 3, 2026, which also trimmed its expectations for the company's share value. Analysts have cited a cautious outlook on how quickly new medical student seats will mature and generate cash.
Adding to the complexity is Afya's pending merger with Yduqs Participações S.A., another major Brazilian education player. The transaction, first announced on September 23, 2026, aims to create a combined entity with over 38,000 medical students, according to an official Yduqs press release. While the companies estimate the tie-up will combine complementary platforms to drive operational synergies, some analysts remain skeptical. Morgan Stanley's research note on November 5, 2026, suggested the merger may add only about 4% in incremental value compared to Afya continuing to operate as a highly profitable standalone business.
Despite the short-term market fluctuations and integration questions, Afya's underlying business remains highly profitable. In its last reported financial results for the first half of 2026, released on August 13, 2026, the company reported a 7.0% year-over-year revenue increase to 1.98 billion reais. It also maintained a robust adjusted EBITDA margin of 46.2%, supported by steady tuition increases and its dominant position in Brazilian medical training. Investors will be watching the November 12, 2026, earnings call to see if the company can maintain this operational momentum.
In your brokerage app
Afya Limited is listed in New York on the Nasdaq under the ticker symbol AFYA. Because it is a primary US listing, retail investors can buy and sell its Class A common shares directly through standard brokerage accounts at Schwab, Fidelity, or Robinhood without incurring foreign custody fees.
